Drug Development Technology: Frost & Sullivan Award goes to Imperacer
The 2008 European Immunoassay Frost & Sullivan Excellence in Technology Award has been awarded to Chimera Biotec. Chimera Biotec is recognized for its pioneering Imperacer® ultra-sensitive immunoassay system, which has a 1000-fold better sensitivity compared to ELISA (Enzyme-linked Immunosorbent Assay), according to the company. With a unique value proposition in the drug development and diagnostic markets, Chimera's innovative Imperacer® products and services have experience widespread market acceptance. “Imperacer® has a proven record for quantifying low-abundant proteins, peptides, biomarkers and a range of “difficult to quantify” markers”, says Mark Spengler, Product Manager at Chimera Biotec. “Among others Imperacer® is currently being used in fields like Alzheimer’s, rheumatoid arthritis, cardiovascular and cancer.”
Launched in 2005, Imperacer® has been successfully used in a number of applications like drug development (preclinic & clinic), vaccine development, diagnostics, anti-doping testing, and proteomics. Imperacer® usually is 3 orders of magnitude more sensitive than any ELISA and is, therefore, mainly used for quantifying low abundant markers that cannot be quantified using conventional ELISA or electrochemiluminescence- technologies (ECL). Imperacer® is characterized by a broad linearity of up to 5 orders of magnitude and can be adapted to sample volumes of less than a microliter. Complementary to Imperacer®, Chimera developed a range of proprietary technologies for eliminating sample interferences (AnySource® technology) and analyte stabilization.
“After having been successfully introduced Imperacer® in research labs in 7 out of TOP 20 pharmaceutical and biotech companies in the U.S. and Switzerland we are now actively exploring broader global markets to expand our services," states Jan Detmers, CEO of Chimera Biotec.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.
